PMID- 33135506
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20211204
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 22
IP  - 4
DP  - 2021 Mar
TI  - An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
PG  - 397-402
LID - 10.1080/14656566.2020.1845650 [doi]
AB  - Introduction: Currently, in prostate cancer, an increasing number of novel drugs 
      are being used to delay its advancement to metastatic castration-resistant 
      prostate cancer (mCRPC). Apalutamide, enzalutamide, and most recently, 
      darolutamide (novel androgen receptor antagonists) have been approved for 
      nonmetastatic castration-resistant prostate cancer (nmCRPC).Areas covered: The 
      authors have evaluated darolutamide, covering all aspects of the clinical 
      development, competence, and safety profile of the drug.Expert opinion: The 
      unique structure of darolutamide is characterized by a high affinity for androgen 
      receptors and detainment of antagonist activity in mutant isoforms of androgen 
      receptors. In clinical practice, this is the main reason that makes darolutamide 
      exceptional in terms of safety and efficacy compared to other drugs in this 
      category. Darolutamide is considered to have the lowest probability for adverse 
      events (AEs) compared to apalutamide and enzalutamide. Future studies, along with 
      real-world clinical data are warranted to improve personalized treatment 
      strategies as well as sequencing treatment between approved novel drugs.
FAU - Moussa, Mohamad
AU  - Moussa M
AD  - Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese 
      University, Beirut, Lebanon.
FAU - Lazarou, Lazaros
AU  - Lazarou L
AD  - 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and 
      Kapodistrian University of Athens, Athens, Greece.
FAU - Dellis, Athanasios
AU  - Dellis A
AD  - 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and 
      Kapodistrian University of Athens, Athens, Greece.
AD  - Department of Surgery, School of Medicine, Aretaieion Hospital, National and 
      Kapodistrian University of Athens, Athens, Greece.
FAU - Abou Chakra, Mohamed
AU  - Abou Chakra M
AD  - Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese 
      University, Beirut, Lebanon.
FAU - Papatsoris, Athanasios
AU  - Papatsoris A
AD  - 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and 
      Kapodistrian University of Athens, Athens, Greece.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201109
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Benzamides)
RN  - 0 (Nitriles)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptors, Androgen)
RN  - 0 (darolutamide)
RN  - 2010-15-3 (Phenylthiohydantoin)
RN  - 93T0T9GKNU (enzalutamide)
SB  - IM
MH  - Androgen Receptor Antagonists/*therapeutic use
MH  - Benzamides
MH  - Humans
MH  - Male
MH  - Nitriles
MH  - Phenylthiohydantoin/analogs & derivatives/therapeutic use
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy
MH  - Pyrazoles/*therapeutic use
MH  - Receptors, Androgen/drug effects
OTO - NOTNLM
OT  - Darolutamide
OT  - apalutamide
OT  - castration resistant
OT  - enzalutamide
OT  - metastatic
OT  - non-metastatic
OT  - prostate cancer
EDAT- 2020/11/03 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/11/02 08:40
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/11/02 08:40 [entrez]
AID - 10.1080/14656566.2020.1845650 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2021 Mar;22(4):397-402. doi: 
      10.1080/14656566.2020.1845650. Epub 2020 Nov 9.